Earnings Call · Q1 FY2023·2023-05-04

Q1 23EPS -44.72%·Rev n/aQ4 22EPS -21.67%·Rev n/aQ3 22EPS -45.00%·Rev n/aQ2 22EPS -29.27%·Rev n/a⚠ consensus missing

Ultragenyx Pharmaceutical Inc. RARE

Joshua Higa — Investor Relations

Emil Kakkis — Chief Executive Officer and President

Erik Harris — Chief Commercial Officer

Aaron Olsen — Senior Vice President and Chief Financial Officer

Eric Crombez — Chief Medical Officer

+3.1%1d on move date+1.2% vs SPY3d+2.8%5d+2.8%

Research tier

Behavioral profile computed for 5 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more RARE calls or request research access.

More RARE calls Browse calls Request research access